Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescript...
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 84
- Registration Number
- NCT05731128
- Locations
- 🇺🇸
Om Research- Site Number : 8400029, Apple Valley, California, United States
🇺🇸Advanced Research Institute - New Port Richey- Site Number : 8400026, New Port Richey, Florida, United States
🇺🇸TLC Clinical Research- Site Number : 8400020, Beverly Hills, California, United States
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Sanofi
- Registration Number
- NCT05726682
Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above
- Conditions
- Interventions
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 203
- Registration Number
- NCT05720455
A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 26
- Registration Number
- NCT05718258
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Site Number : 8400002, Miami, Florida, United States
🇺🇸Nucleus Network Site Number : 8400001, Saint Paul, Minnesota, United States
🇩🇪Investigational Site Number : 2760001, Kiel, Germany
A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 7
- Registration Number
- NCT05712278
- Locations
- 🇺🇸
~MD Anderson Cancer Center Site Number : 8400002, Houston, Texas, United States
🇺🇸University of Nebraska Medical Center Site Number : 8400003, Omaha, Nebraska, United States
🇺🇸Albert Einstein College of Medicine Site Number : 8400001, Bronx, New York, United States
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 74
- Registration Number
- NCT05704049
- Locations
- 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺Investigational Site Number : 0360001, Fitzroy, Victoria, Australia
A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT05684341
- Locations
- 🇨🇳
Tri-Service General Hospital - Investigational Site Number: 1580014, Taipei city, Taiwan
🇨🇳Kaohsiung Veterans General Hospital - Investigational site number 1580010, Kaohsiung, Taiwan
🇨🇳Far-Eastern Memorial Hospital - Investigational Site Number: 1580004, New Taipei city, Taiwan
Dupilumab-pediatric Skin Barrier Function and Lipidomics Study in Patients With Atopic Dermatitis in China
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 34
- Registration Number
- NCT05680298
- Locations
- 🇨🇳
Beijing Children's hospital, Beijing, China
Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry)
- Conditions
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT05671770
- Locations
- 🇦🇪
Cleveland Clinic AbuDhabi, Abu Dhabi, United Arab Emirates
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 70
- Registration Number
- NCT05669989
- Locations
- 🇳🇿
Investigational Site Number : 5540002, Auckland, New Zealand
🇺🇸Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺Investigational Site Number : 0360006, Blacktown, New South Wales, Australia